Lithium containing aluminosilicate glasses

US11572302B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11572302-B2
Application numberUS-202016837995-A
CountryUS
Kind codeB2
Filing dateApr 1, 2020
Priority dateNov 30, 2016
Publication dateFeb 7, 2023
Grant dateFeb 7, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may have a surface compressive stress of at least 350 MPa.

First claim

Opening claim text (preview).

What is claimed is: 1. A glass pharmaceutical package having a glass composition comprising: from greater than or equal to 68.00 mol % to less than or equal to 81.00 mol % SiO 2 ; from greater than or equal to 4.00 mol % to less than or equal to 11.00 mol % Al 2 O 3 ; from greater than or equal to 0.10 mol % to less than or equal to 16.00 mol % Li 2 O; from greater than or equal to 0.10 mol % to less than or equal to 12.00 mol % Na 2 O; from greater than or equal to 0.00 mol % to less than or equal to 5.00 mol % K 2 O; from greater than or equal to 0.10 mol % to less than or equal to 8.00 mol % MgO; from greater than or equal to 0.10 mol % to less than or equal to 5.00 mol % CaO; from greater than or equal to 0.00 mol % to less than or equal to 0.20 mol % fining agent, wherein the glass pharmaceutical package is delamination resistant, the glass pharmaceutical package has class 1 or class 2 chemical durability in acid, base, and water, and the glass pharmaceutical package is strengthened by ion exchange and comprises: a surface compressive stress of at least 350 MPa; a central tension from greater than or equal to 5 MPa to less than or equal to 160 MPa; and a depth of compression from greater than or equal to 0.05t to less than or equal to 0.25t. 2. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises from greater than or equal to 1.50 mol % to less than or equal to 16.00 mol % Li 2 O. 3. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises from greater than or equal to 0.10 mol % to less than or equal to 7.50 mol % MgO. 4. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises greater than 0.00 mol % of the fining agent, and the fining agent is selected from the group consisting of SnO 2 , CeO 2 , As 2 O 3 , Sb 2 O 3 , Cl − , S − , F − , or Fe 2 O 3 . 5. The glass pharmaceutical package according to claim 4 wherein the fining agent consists of SnO 2 . 6. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is substantially free of at least one of B 2 O 3 , SrO, BaO, and ZrO 2 . 7. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is substantially free of B 2 O 3 , SrO, BaO, and ZrO 2 . 8. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a ratio of (Li 2 O+Na 2 O+K 2 O)/(SiO2+Al 2 O 3 ) that is from greater than or equal to 0.05 to less than or equal to 0.50. 9. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a ratio of (Li 2 O+Na 2 O+K 2 O)/(SiO 2 +Al 2 O 3 ) that is from greater than or equal to 0.05 to less than or equal to 0.15. 10. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a density from greater than or equal to 2.25 g/cm 3 to less than or equal to 2.50 g/cm 3 . 11. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a molar volume from greater than or equal to 24.00 cm 3 /mol to less than or equal to 27.00 cm 3 /mol. 12. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package has a delamination factor less than or equal to 10. 13. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises a strain point from greater than or equal to 450° C. to less than or equal to 625° C. 14. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises an annealing point from greater than or equal to 500° C. to less than or equal to 675° C. 15. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises a softening point from greater than or equal to 750° C. to less than or equal to 950° C. 16. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises a coefficient of thermal expansion (CTE) from greater than or equal to 4.20 ppm/° C. to less than or equal to 7.00 ppm/° C. 17. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises a Log of liquidus viscosity from greater than or equal to 3.50 poise to less than or equal to 6.00 poise. 18. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises a Young's modulus from greater than or equal to 10.00 mpsi to less than or equal to 12.00 mpsi. 19. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises a shear modulus from greater than or equal to 4.00 mpsi to less than or equal to 5.00 mpsi. 20. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm 2 to less than or equal to 1.5 mg/dm 2 . 21. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm 2 to less than or equal to 0.7 mg/dm 2 . 22. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm 2 to less than or equal to 175 mg/dm 2 . 23. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm 2 to less than or equal to 75 mg/dm 2 . 24. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μg/g to less than or equal to 100 μg/g. 25. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μg/g to less than or equal to 62 μg/g. 26. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a diffusivity of potassium ions at 420° C. from greater than or equal to 0.50 μm 2 /hr to less than or equal to 15.00 μm 2 /hr. 27. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a stored energy of less than or equal to about 15.00 J/m 2 . 28. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a stored energy of greater than or equal to 17.00 J/m 2 .

Assignees

Inventors

Classifications

  • C03C3/087Primary

    containing calcium oxide, e.g. common sheet or container glass · CPC title

  • Containers specially adapted for medical or pharmaceutical purposes (capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00) · CPC title

  • containing an oxide of a divalent metal, e.g. an oxide of zinc · CPC title

  • to perform ion-exchange between alkali ions (C03C21/005 takes precedence) · CPC title

  • with 40% to 90% silica, by weight {(C03C3/045 takes precedence)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11572302B2 cover?
A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delami…
Who is the assignee on this patent?
Corning Inc
What technology area does this patent fall under?
Primary CPC classification C03C3/087. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).